毕得医药：2025年净利润1.52亿元，同比增长29.61%

Core Viewpoint - Bid Pharma reported a revenue of 1.324 billion yuan for the fiscal year 2025, representing a year-on-year growth of 20.13% [1] - The net profit attributable to the parent company reached 152 million yuan, an increase of 29.61% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 133 million yuan, up by 27.98% year-on-year [1] Group 1 - The company adheres to a global development strategy while focusing on expanding its domestic market and strengthening overseas marketing efforts, leading to continuous growth in overseas business [1] - The company is actively increasing product innovation and optimizing product structure to drive value creation through research and development [1] - The company is advancing intelligent operations to enhance management efficiency while achieving steady revenue growth, with improvements in gross margin and profit margin indicators [1]